Cempra Inc. (CEMP) 18.75 $CEMP
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that research findings for the company's lead product, solithromycin, will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston on June 16-20, 2016.
CEMP: 18.75 (-0.11)
Cempra to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2016 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 11:30 a.m. EDT on Thursday, June 9, 2016 in New York City.
CEMP: 18.75 (-0.11)
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
GlobeNewswire - Wed May 25, 3:30PM CDT
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM)
CEMP: 18.75 (-0.11)
Cempra to Present Solithromycin IV Data at ATS 2016
GlobeNewswire - Thu May 12, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2016, May 13-18, to be held in San Francisco.
CEMP: 18.75 (-0.11)
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Sun May 01, 4:00PM CDT
Solithromycin is designated by FDA as a Qualified Infectious Disease Product
CEMP: 18.75 (-0.11)
Cempra to Report First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report first quarter 2016 financial results before the open of U.S. financial markets on Monday, May 2, 2016. Cempra management will host a webcast and conference call at 8:00 a.m. ET that day to discuss the financial results and provide a corporate update.
CEMP: 18.75 (-0.11)
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.
CEMP: 18.75 (-0.11)
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
GlobeNewswire - Mon Mar 07, 6:00AM CST
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years
CEMP: 18.75 (-0.11)
Cempra Reports Positive Data on Antibiotic Solithromycin
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 1:10PM CST
Cempra (CEMP) announced positive results from the phase III SOLITAIRE-ORAL study on solithromycin for the treatment of community-acquired bacterial pneumonia.
AGN: 243.08 (-4.32), LGND: 114.00 (-1.08), CEMP: 18.75 (-0.11), SNY: 39.45 (-1.41)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 243.08 (-4.32), AZN: 27.81 (-1.15), CEMP: 18.75 (-0.11), APHB: 1.69 (-0.06), GLPG: 55.02 (-1.86)
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra's Oral Solithromycin in Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Feb 05, 6:00AM CST
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone
CEMP: 18.75 (-0.11)
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 6:30AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 5th Annual Leerink Partners Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 8:25 a.m. ET on Wednesday, February 10, 2016 at the Waldorf Astoria in New York.
CEMP: 18.75 (-0.11)
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin
GlobeNewswire - Mon Feb 01, 6:30AM CST
Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, and Macrolide Pharmaceuticals, Inc., a preclinical company focused on the development of novel macrolide antibacterials, today announced an agreement where Macrolide will use its novel, proprietary synthesis technology to provide Cempra with a fully synthetic process for its late-stage investigational macrolide antibiotic, solithromycin. Solithromycin has completed Phase 3 clinical trials and a New Drug Application (NDA) is in progress for the treatment of community acquired bacterial pneumonia. Solithromycin is currently manufactured using clarithromycin, a fermentation-derived antibiotic, as the starting material. Based on ground-breaking technology developed by Andrew G. Myers, Ph.D., and colleagues at Harvard University, Macrolide Pharmaceuticals will partner with Cempra with the goal of developing a fully synthetic, cost-competitive manufacturing process for solithromycin. An alternative fully synthetic process could provide manufacturing and supplier flexibility by reducing dependence upon fermentation-derived starting materials.
CEMP: 18.75 (-0.11)
Cempra, Inc. (Nasdaq: CEMP) to Ring the Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Jan 27, 9:00AM CST
What:
CEMP: 18.75 (-0.11), NDAQ: 65.63 (-0.03)
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary
GlobeNewswire - Tue Jan 26, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will ring the Closing Bell at the Nasdaq Stock Exchange to recognize the 10 anniversary of the Company's creation. Cempra founder, president and chief executive officer Prabhavathi Fernandes, Ph.D., will be joined at the Nasdaq by Cempra employees, investors and colleagues.
CEMP: 18.75 (-0.11)
Cempra Slumps: CEMP Falls 10.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 7:48AM CST
Cempra (CEMP) saw a big move last session, as the company's shares fell by over 10% on the day.
CEMP: 18.75 (-0.11), CORT: 5.58 (+0.11)
Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 07, 2:08PM CST
What: At 2:30 p.m. EST, Epizyme is down 11%, Akebia Therapeutics is down 10%, and Cempra is down 11%. All three biotechs are down for the exact same reason: They sold additional shares through secondary offerings. So what: Companies...
TXMD: 8.95 (-0.08), IBB: 267.51 (-6.07), EPZM: 11.91 (-0.35), AKBA: 8.33 (-0.15), CEMP: 18.75 (-0.11)
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that research findings for the company's lead product, solithromycin, will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston on June 16-20, 2016.
CEMP: 18.75 (-0.11)
Cempra to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2016 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 11:30 a.m. EDT on Thursday, June 9, 2016 in New York City.
CEMP: 18.75 (-0.11)
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
GlobeNewswire - Wed May 25, 3:30PM CDT
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM)
CEMP: 18.75 (-0.11)
Cempra to Present Solithromycin IV Data at ATS 2016
GlobeNewswire - Thu May 12, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2016, May 13-18, to be held in San Francisco.
CEMP: 18.75 (-0.11)
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Sun May 01, 4:00PM CDT
Solithromycin is designated by FDA as a Qualified Infectious Disease Product
CEMP: 18.75 (-0.11)
Cempra to Report First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report first quarter 2016 financial results before the open of U.S. financial markets on Monday, May 2, 2016. Cempra management will host a webcast and conference call at 8:00 a.m. ET that day to discuss the financial results and provide a corporate update.
CEMP: 18.75 (-0.11)
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.
CEMP: 18.75 (-0.11)
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
GlobeNewswire - Mon Mar 07, 6:00AM CST
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years
CEMP: 18.75 (-0.11)
Cempra Reports Positive Data on Antibiotic Solithromycin
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 1:10PM CST
Cempra (CEMP) announced positive results from the phase III SOLITAIRE-ORAL study on solithromycin for the treatment of community-acquired bacterial pneumonia.
AGN: 243.08 (-4.32), LGND: 114.00 (-1.08), CEMP: 18.75 (-0.11), SNY: 39.45 (-1.41)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 243.08 (-4.32), AZN: 27.81 (-1.15), CEMP: 18.75 (-0.11), APHB: 1.69 (-0.06), GLPG: 55.02 (-1.86)
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra's Oral Solithromycin in Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Feb 05, 6:00AM CST
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone
CEMP: 18.75 (-0.11)
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 6:30AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 5th Annual Leerink Partners Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 8:25 a.m. ET on Wednesday, February 10, 2016 at the Waldorf Astoria in New York.
CEMP: 18.75 (-0.11)
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin
GlobeNewswire - Mon Feb 01, 6:30AM CST
Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, and Macrolide Pharmaceuticals, Inc., a preclinical company focused on the development of novel macrolide antibacterials, today announced an agreement where Macrolide will use its novel, proprietary synthesis technology to provide Cempra with a fully synthetic process for its late-stage investigational macrolide antibiotic, solithromycin. Solithromycin has completed Phase 3 clinical trials and a New Drug Application (NDA) is in progress for the treatment of community acquired bacterial pneumonia. Solithromycin is currently manufactured using clarithromycin, a fermentation-derived antibiotic, as the starting material. Based on ground-breaking technology developed by Andrew G. Myers, Ph.D., and colleagues at Harvard University, Macrolide Pharmaceuticals will partner with Cempra with the goal of developing a fully synthetic, cost-competitive manufacturing process for solithromycin. An alternative fully synthetic process could provide manufacturing and supplier flexibility by reducing dependence upon fermentation-derived starting materials.
CEMP: 18.75 (-0.11)
Cempra, Inc. (Nasdaq: CEMP) to Ring the Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Jan 27, 9:00AM CST
What:
CEMP: 18.75 (-0.11), NDAQ: 65.63 (-0.03)
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary
GlobeNewswire - Tue Jan 26, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will ring the Closing Bell at the Nasdaq Stock Exchange to recognize the 10 anniversary of the Company's creation. Cempra founder, president and chief executive officer Prabhavathi Fernandes, Ph.D., will be joined at the Nasdaq by Cempra employees, investors and colleagues.
CEMP: 18.75 (-0.11)
Cempra Slumps: CEMP Falls 10.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 7:48AM CST
Cempra (CEMP) saw a big move last session, as the company's shares fell by over 10% on the day.
CEMP: 18.75 (-0.11), CORT: 5.58 (+0.11)
Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 07, 2:08PM CST
What: At 2:30 p.m. EST, Epizyme is down 11%, Akebia Therapeutics is down 10%, and Cempra is down 11%. All three biotechs are down for the exact same reason: They sold additional shares through secondary offerings. So what: Companies...
TXMD: 8.95 (-0.08), IBB: 267.51 (-6.07), EPZM: 11.91 (-0.35), AKBA: 8.33 (-0.15), CEMP: 18.75 (-0.11)
